Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bluebird Bio (NASDAQ:BLUE) and Acelrx (NASDAQ:ACRX).
Bluebird Bio (BLUE)
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Bluebird Bio today and set a price target of $186. The company’s shares closed on Friday at $126.09, close to its 52-week low of $123.34.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 11.0% and a 63.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, DBV Technologies SA – American, and Global Blood Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bluebird Bio with a $210.89 average price target, which is a 67.3% upside from current levels. In a report issued on October 5, Maxim Group also maintained a Hold rating on the stock.
.
See today’s analyst top recommended stocks >>
Acelrx (ACRX)
Jefferies analyst Matthew Andrews upgraded Acelrx to Buy today and set a price target of $8. The company’s shares closed on Thursday at $3.98.
According to TipRanks.com, Andrews is a 5-star analyst with an average return of 32.3% and a 45.9% success rate. Andrews covers the Healthcare sector, focusing on stocks such as Liquidia Technologies Inc, Spectrum Pharmaceuticals, and Gemphire Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Acelrx with a $6.25 average price target, implying a 57.0% upside from current levels. In a report issued on October 1, Cantor Fitzgerald also maintained a Buy rating on the stock with a $6 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACRX:
